临床试验/ACTRN12607000191493

ACTRN12607000191493已完成1 期

Phase I trial to assess the safety of adoptive transfer of cytotoxic T cells specific for Epstein Barr Virus (EBV) latent membrane proteins (LMP) in patients with Stage III and IV nasopharyngeal carcinoma

Queensland Institute of Medical Research0 个研究点目标入组 10 人开始时间: 2007年4月3日最近更新: 2020年1月13日

适应症

试验速览

阶段: 1 期
状态: 已完成
发起方: Queensland Institute of Medical Research
入组人数: 10

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Non-randomised trial
主要目的: Treatment
盲法: Open (masking not used)

入排标准

年龄范围: 15 Years 至 ot stated（—）
性别: All

入选标准

•1.Stage III or IV nasopharyngeal carcinoma as defined by the 6th edition of the UICC TNM staging. 2. Geographically accessible for follow up 3.Informed consent (from patient, or patient and parent/guardian if aged < 16 years) 4.ECOG performance status 1, 2 or 3 (see Appendix G). 5.Life expectancy of at least three months.

排除标准

•1.EBV negative tumour, as found in project P4902.Inability to identify a LMP peptide to stimulate CTL cultures3.Positive serology for HIV, 4.Serology indicating active HBV infection or carrier status for HBV 5.Serology indicating active HCV infection6.Significant non –malignant disease 7.Psychiatric, addictive or any condition which may compromise the ability to participate in this trial8.Prior cancers, except those diagnosed > five years ago with no evidence of disease recurrence and clinical expectation of recurrence <5%, or successfully treated non-melanoma skin cancer, or carcinoma in situ of the cervix.9.Currently receiving immunosuppressive therapy, including corticosteroids.10.Pregnancy, or unwilling to use adequate contraception.

研究者

发起方

Queensland Institute of Medical Research

相似试验

Phase I trial of multi-virus-specific T cells for paediatric haploidentical -stem cell transplant recipientsHaplo-identical haematopoietic stem cell transplantationBlood - Haematological diseasesInfection - Other infectious diseases

ACTRN12620000141943QIMR Berghofer Medical Research Institute20

A Phase 1 trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of AS-0871 and to evaluate the relative bioavailability and the food effect of new oral formulations of AS-0871 in healthy subjects.

NL-OMON53402Carna Biosciences, Inc.40

A Phase I clinical trial to evaluate the safety and pharmacokinetics of SHR0302 base ointment at single dose and multiple dose in healthy adult subjectsAtopic dermatitisSkin - Dermatological conditions

ACTRN12619001443189Reistone Biopharma Co., Ltd.32

A phase 1 clinical trial to evaluate the safety and pharmacokinetic characteristics after administration of fixed-dose combination of NGL-101 and loose-combination of each component in healthy adult volunteers

KCT0007258Chungbuk National University Hospital40

Comparison of pharmacokinetics between administration of fixed-dose combination or loose combination of HUG186(Bazedoxifene and Cholecalciferol)

KCT0003839Huons52